News
Bone Health Technologies acquires Brooklyn-based health start-up
The US medtech company Bone Health Technologies has acquired the Brooklyn-based start-up Wellen to improve health outcomes for people at risk of osteoporosis and bone fractures.
Wellen is a health tech start-up that seeks to support active ageing and empower women to live longer and healthier lives.
The company, which has developed a programme for women suffering from osteoporosis and osteopenia, aims to provide “science-based” solutions to improve bone health and overall wellbeing.
The acquisition of Wellen is a major step toward achieving Bone Health Technologies’ vision of a multi-modal bone health solution, anchored by the its FDA-cleared Osteoboost vibration therapy belt launching later this year.
“We’re thrilled to welcome Wellen to the Bone Health Technologies team,” said Laura Yecies, CEO of Bone Health Technologies.
“One in two women and one in four men will suffer an osteoporotic fracture in their lifetime. The Wellen team have built the gold standard for personalised exercise-based care designed by physical therapists to strengthen bones and reduce the risk of falls and fractures. The Wellen programme will bring tremendous value to our platform.”
Priya Patel, Wellen CEO, said: “Anticipation is high for the launch of Osteoboost among both patients and healthcare professionals, and our science-backed osteoporosis exercise platform is a natural fit.
“New treatments for low bone mass have been few and far between for a long time and too often have focused on a single type of treatment. I couldn’t be happier to join Bone Health Technologies and continue making a difference for people with low bone density.
“Osteoboost is the therapeutic anchor to Bone Health Technologies’ holistic, non-pharmacological approach to bone health,” Patel added. “By layering customised exercise, nutrition, tracking, and more, we will be able to offer patients not only convenience but better results and a stronger, more active life.”
To receive the Femtech World newsletter, sign up here.
Diagnosis
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Pregnancy
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Entrepreneur
Kindbody unveils next-gen fertility platform
-
Insight4 weeks agoDesigner perfumes recalled over banned chemical posing fertility risk
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Insight3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Menopause3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur6 days agoUS startup builds wearable hormone tracker
-
Menopause2 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
Menopause2 weeks agoStudy reveals gap between perimenopause expectations and experience







3 Comments